Vivek Subbiah: Honored to speak at the special ESMO and ASCO joint session at ESMO24
Vivek Subbiah shared a post on LinkedIn:
”Announcement: Precision medicine and tumor-agnostic drug development take center stage European Society for Medical Oncology Annual Congress!
Honored to be invited to speak at the SPECIAL ESMO and ASCO joint session in Barcelona, Spain on ‘Tumour-agnostic drug development’ at the ESMO congress 2024.
Chaired jointly by the amazing ESMO President Andres Cervantes and our incredible American Society of Clinical Oncology (ASCO) President Robin Zon join us for an exclusive session Prime time on Sunday ‘Novel Pathways for Development of Precision Therapeutics in Molecular Oncology.’
- Date: 10:15 – 11:45 AM.
- Location: Oviedo Auditorium – Hall 3.
- When: Sunday, 15.09.2024.
Our amazing Julie Gralow Chief Medical Officer American Society of Clinical Oncology (ASCO) will be talking about Regulatory sandboxes: How to synchronize safe, timely regulation with scientific breakthroughs in molecular ‘niches’ .”
Read further.
Source: Vivek Subbiah/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.